Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells
Authors
Keywords
-
Journal
Molecular Oncology
Volume 5, Issue 1, Pages 93-104
Publisher
Wiley
Online
2010-10-17
DOI
10.1016/j.molonc.2010.10.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Integrated Study of Aberrant Gene Copy Number and Gene Expression in GIST and LMS
- (2014) Da Yang et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Is Autophagy Rather Than Apoptosis the Regression Driver in Imatinib-Treated Gastrointestinal Stromal Tumors?
- (2014) Francesca Miselli et al. Translational Oncology
- Role for the Proapoptotic Factor BIM in Mediating Imatinib-induced Apoptosis in a c-KIT-dependent Gastrointestinal Stromal Tumor Cell Line
- (2010) Peter M. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)
- (2010) A. Gupta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the Bcl-2 family of proteins in Hodgkin lymphoma:in vitrocytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737
- (2009) Aarthi Jayanthan et al. LEUKEMIA & LYMPHOMA
- Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro
- (2009) Jheri J Dupart et al. Molecular Cancer
- Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment
- (2009) Robert S. Benjamin et al. SEMINARS IN ONCOLOGY
- A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis
- (2008) John C. McAuliffe et al. ANNALS OF SURGICAL ONCOLOGY
- The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
- (2008) L. Paoluzzi et al. BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Imatinib Mesylate Induces Quiescence in Gastrointestinal Stromal Tumor Cells through the CDH1-SKP2-p27Kip1Signaling Axis
- (2008) Ying Liu et al. CANCER RESEARCH
- Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
- (2008) Toshirou Nishida et al. CANCER SCIENCE
- Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
- (2008) Narasimhan P. Agaram et al. GENES CHROMOSOMES & CANCER
- Clinical significance of oncogenicKITandPDGFRAmutations in gastrointestinal stromal tumours
- (2008) J Lasota et al. HISTOPATHOLOGY
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of kinase inhibitor resistance mechanisms in GIST
- (2008) B Liegl et al. JOURNAL OF PATHOLOGY
- Preclinicalversusclinical drug combination studies
- (2008) Ting-Chao Chou LEUKEMIA & LYMPHOMA
- Novel approaches to imatinib-and sunitinib-resistant GIST
- (2008) Peter Reichardt Current Oncology Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search